Neuroscience
Health Canada Decision on Adderall
From today's
Globe and Mail:
Yanking ADHD drug angers clinicians
Health Canada's interpretation of safety data behind its abrupt decision to halt the sale of Adderall is being questioned
By ANDRÉ PICARD
Friday, February 11, 2005 Updated at 7:50 AM EST
The Globe and Mail
Health Canada has stripped a pharmaceutical company of the right to sell a popular drug used for the treatment of hyperactive children in Canada after talks about withdrawing the medication voluntarily broke down.
The highly unusual move -- market authorization has not been withdrawn from any of the 5,000 prescription drugs on the Canadian market since 1999 -- came after Shire Biochem Inc. revealed that at least 20 people taking Adderall XR had died suddenly, and 12 others suffered debilitating strokes. All the deaths and strokes were in the United States. Most involved children who died of stroke, which occurs when a blood vessel to the brain is blocked by a blood clot or bursts, cutting off oxygen to the brain.
[ ... Read the full article ... ]~Click here for the English text of the Health Canada Advisory. (Also available in French.)
Click here for Shire Biochem press release about the Health Canada decision.
-
Drug Advertising Opposed
A Health Council Canada report called Direct-to-Consumer Advertising of Prescription Drugs in Canada: What are the Public Health Implications? details research on pharmamarketing and its impact on health care. In Canada only two forms of advertising...
-
Concussion In Sport
From the CBC: Concussion prevention effort features mobile app Four sports organizations partner with government on new education programs CBC News Posted: Jan 19, 2012 11:27 AM ET Last Updated: Jan 19, 2012 3:19 PM ET [snip] Four sports organizations...
-
Election Day In Canada
Today is election day in Canada. Vote! Here is a discussion of one of the health care issues in Canada: a shortage in the number of physicians: From The CBC: Why MDs are scarce and what can be done about it Read the article...
-
Reminyl (galantamine Hydrobromide) (continued)
Safety Concerns Reported on J.& J. Alzheimer's Drug
By ANDREW POLLACK
New York Times
Published: January 22, 2005
Regulators are reviewing the safety of the Alzheimer's disease drug Reminyl after data from two clinical trials indicated...
-
Sickle Cell Clinical Study Halted
Risk of Strokes Halts Sickle Cell Study
By Daniel Yee
Associated Press
The Washington Post
Monday, December 6, 2004; Page A02
ATLANTA, Dec. 5 -- A study aimed at determining whether some children with sickle cell anemia could be weaned off blood...
Neuroscience